Target intelligence / Profile preview

Off-target genomic loci with partial complementarity to the G6PC guide RNA (G6PC off-target sites)

Target
G6PC off-target sites
Molecular classification
Genomic DNA
01

Overview

Off-target genomic loci with partial complementarity to the G6PC guide RNA are unintended DNA sequences that share significant sequence homology with the target site in the Glucose-6-Phosphatase Catalytic Subunit (G6PC) gene (Chou et al., 2018, Nature Reviews Endocrinology). In CRISPR-Cas9 based therapies for Glycogen Storage Disease Type Ia (GSDIa), the guide RNA (gRNA) is designed to direct the Cas9 nuclease to the G6PC locus; however, the enzyme may also bind and cleave these off-target sites due to partial complementarity (Zhang et al., 2015, Science). Such unintended cleavage can lead to permanent mutations, including insertions and deletions (indels) or large-scale chromosomal rearrangements, which may disrupt essential genes or regulatory elements (Fu et al., 2013, Nature Biotechnology). These events pose a substantial safety risk, potentially leading to cellular transformation or loss of function in non-target pathways. Consequently, the identification and characterization of these loci using methods like GUIDE-seq or CIRCLE-seq are mandatory steps in the preclinical evaluation of G6PC-targeting gene editors (Tsai et al., 2015, Nature Biotechnology). Minimizing activity at these loci is a primary goal in the development of high-fidelity Cas9 variants and optimized gRNA architectures for treating metabolic disorders.

Other names
CRISPR off-target sitesNon-specific genomic cleavage sitesG6PC gRNA off-targetsUnintended genomic modifications
02

Mechanism of action

Unintended double-strand breaks (DSBs) followed by error-prone DNA repair mechanisms such as non-homologous end joining (NHEJ) or homology-directed repair (HDR) at non-target genomic sites (Fu et al., 2013, Nature Biotechnology).

03

Biological functions

Genomic stability maintenance
04

Disease associations

GenotoxicityOncogenesisGenomic instability
05

Safety considerations

Unintended mutations in coding or regulatory regionsChromosomal rearrangements and translocationsActivation of proto-oncogenesInactivation of tumor suppressor genesPotential for cellular transformation
06

Interacting drugs

CRISPR-Cas9 gene editing complexes (experimental)
07

Biomarkers

Off-target mutation frequencyIndel formation at predicted sitesChromosomal translocationsGUIDE-seq read counts

Beyond the preview

Go deeper on Off-target genomic loci with partial complementarity to the G6PC guide RNA (G6PC off-target sites).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Off-target genomic loci with partial complementarity to the G6PC guide RNA (G6PC off-target sites).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call